High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancer
Objective: While immunotherapy holds great potential for triple-negative breast cancer (TNBC), the lack of non-invasive biomarkers to identify beneficiaries limits the application. Methods: Paired baseline, on-treatment, and post-treatment plasma samples were collected from 195 TNBC patients receivi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2025-07-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | https://www.cancerbiomed.org/content/22/7/854 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849410183364608000 |
|---|---|
| author | Yuling Xiao Hang Zhang Yi Xiao Ying Wang Jing Zhang Qi Hua Pengchen Hu Xinyan Lyu Weihua Shou Xin Hu Zhiming Shao Yizhou Jiang Wei Huang Jinxiu Shi |
| author_facet | Yuling Xiao Hang Zhang Yi Xiao Ying Wang Jing Zhang Qi Hua Pengchen Hu Xinyan Lyu Weihua Shou Xin Hu Zhiming Shao Yizhou Jiang Wei Huang Jinxiu Shi |
| author_sort | Yuling Xiao |
| collection | DOAJ |
| description | Objective: While immunotherapy holds great potential for triple-negative breast cancer (TNBC), the lack of non-invasive biomarkers to identify beneficiaries limits the application. Methods: Paired baseline, on-treatment, and post-treatment plasma samples were collected from 195 TNBC patients receiving anti-PD-1 immunotherapy in this retrospective study conducted at the Fudan University Shanghai Cancer Center (FUSCC) for sequential high-precision proteomic profiling. Results: ARG1, NOS3, and CD28 were identified as plasma proteins significantly associated with the response to immunotherapy in neoadjuvant settings or in advanced stages of TNBC. Matched single-cell RNA sequencing data were incorporated to correlate peripheral plasma with the tumor microenvironment. Furthermore, the Plasma Immuno Prediction Score was developed to demonstrate significant predictive power for evaluating the efficacy and prognosis of patients undergoing neoadjuvant immunotherapy. Conclusions: The results underscore the importance of systemic immunity in the immunotherapy response and support the use of plasma protein profiles as a feasible tool for enhancing personalized management of immunotherapy in breast cancer. |
| format | Article |
| id | doaj-art-e83e11393def44efaf957112f8cc31c9 |
| institution | Kabale University |
| issn | 2095-3941 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | China Anti-Cancer Association |
| record_format | Article |
| series | Cancer Biology & Medicine |
| spelling | doaj-art-e83e11393def44efaf957112f8cc31c92025-08-20T03:35:12ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412025-07-0122785487010.20892/j.issn.2095-3941.2025.0038High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancerYuling Xiao0Hang Zhang1Yi Xiao2Ying Wang3Jing Zhang4Qi Hua5Pengchen Hu6Xinyan Lyu7Weihua Shou8Xin Hu9Zhiming Shao10Yizhou Jiang11Wei Huang12Jinxiu Shi13Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, ChinaKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, ChinaKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, ChinaShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Shanghai 200237, ChinaShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Shanghai 200237, ChinaShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Shanghai 200237, ChinaShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Shanghai 200237, ChinaShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Shanghai 200237, ChinaShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Shanghai 200237, ChinaKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, ChinaKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, ChinaKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, ChinaShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Shanghai 200237, ChinaShanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), Shanghai 200237, ChinaObjective: While immunotherapy holds great potential for triple-negative breast cancer (TNBC), the lack of non-invasive biomarkers to identify beneficiaries limits the application. Methods: Paired baseline, on-treatment, and post-treatment plasma samples were collected from 195 TNBC patients receiving anti-PD-1 immunotherapy in this retrospective study conducted at the Fudan University Shanghai Cancer Center (FUSCC) for sequential high-precision proteomic profiling. Results: ARG1, NOS3, and CD28 were identified as plasma proteins significantly associated with the response to immunotherapy in neoadjuvant settings or in advanced stages of TNBC. Matched single-cell RNA sequencing data were incorporated to correlate peripheral plasma with the tumor microenvironment. Furthermore, the Plasma Immuno Prediction Score was developed to demonstrate significant predictive power for evaluating the efficacy and prognosis of patients undergoing neoadjuvant immunotherapy. Conclusions: The results underscore the importance of systemic immunity in the immunotherapy response and support the use of plasma protein profiles as a feasible tool for enhancing personalized management of immunotherapy in breast cancer.https://www.cancerbiomed.org/content/22/7/854triple-negative breast cancerimmunotherapynon-invasive biomarkersefficacy predictionplasma proteomic profiling |
| spellingShingle | Yuling Xiao Hang Zhang Yi Xiao Ying Wang Jing Zhang Qi Hua Pengchen Hu Xinyan Lyu Weihua Shou Xin Hu Zhiming Shao Yizhou Jiang Wei Huang Jinxiu Shi High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancer Cancer Biology & Medicine triple-negative breast cancer immunotherapy non-invasive biomarkers efficacy prediction plasma proteomic profiling |
| title | High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancer |
| title_full | High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancer |
| title_fullStr | High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancer |
| title_full_unstemmed | High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancer |
| title_short | High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancer |
| title_sort | high precision immune related plasma proteomics profiling predicts response to immunotherapy in patients with triple negative breast cancer |
| topic | triple-negative breast cancer immunotherapy non-invasive biomarkers efficacy prediction plasma proteomic profiling |
| url | https://www.cancerbiomed.org/content/22/7/854 |
| work_keys_str_mv | AT yulingxiao highprecisionimmunerelatedplasmaproteomicsprofilingpredictsresponsetoimmunotherapyinpatientswithtriplenegativebreastcancer AT hangzhang highprecisionimmunerelatedplasmaproteomicsprofilingpredictsresponsetoimmunotherapyinpatientswithtriplenegativebreastcancer AT yixiao highprecisionimmunerelatedplasmaproteomicsprofilingpredictsresponsetoimmunotherapyinpatientswithtriplenegativebreastcancer AT yingwang highprecisionimmunerelatedplasmaproteomicsprofilingpredictsresponsetoimmunotherapyinpatientswithtriplenegativebreastcancer AT jingzhang highprecisionimmunerelatedplasmaproteomicsprofilingpredictsresponsetoimmunotherapyinpatientswithtriplenegativebreastcancer AT qihua highprecisionimmunerelatedplasmaproteomicsprofilingpredictsresponsetoimmunotherapyinpatientswithtriplenegativebreastcancer AT pengchenhu highprecisionimmunerelatedplasmaproteomicsprofilingpredictsresponsetoimmunotherapyinpatientswithtriplenegativebreastcancer AT xinyanlyu highprecisionimmunerelatedplasmaproteomicsprofilingpredictsresponsetoimmunotherapyinpatientswithtriplenegativebreastcancer AT weihuashou highprecisionimmunerelatedplasmaproteomicsprofilingpredictsresponsetoimmunotherapyinpatientswithtriplenegativebreastcancer AT xinhu highprecisionimmunerelatedplasmaproteomicsprofilingpredictsresponsetoimmunotherapyinpatientswithtriplenegativebreastcancer AT zhimingshao highprecisionimmunerelatedplasmaproteomicsprofilingpredictsresponsetoimmunotherapyinpatientswithtriplenegativebreastcancer AT yizhoujiang highprecisionimmunerelatedplasmaproteomicsprofilingpredictsresponsetoimmunotherapyinpatientswithtriplenegativebreastcancer AT weihuang highprecisionimmunerelatedplasmaproteomicsprofilingpredictsresponsetoimmunotherapyinpatientswithtriplenegativebreastcancer AT jinxiushi highprecisionimmunerelatedplasmaproteomicsprofilingpredictsresponsetoimmunotherapyinpatientswithtriplenegativebreastcancer |